BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30627774)

  • 1. Outcomes After Transarterial Embolization of Neuroendocrine Tumor Liver Metastases Using Spherical Particles of Different Sizes.
    Zener R; Yoon H; Ziv E; Covey A; Brown KT; Sofocleous CT; Thornton RH; Boas FE
    Cardiovasc Intervent Radiol; 2019 Apr; 42(4):569-576. PubMed ID: 30627774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors.
    Fiore F; Del Prete M; Franco R; Marotta V; Ramundo V; Marciello F; Di Sarno A; Carratù AC; de Luca di Roseto C; Colao A; Faggiano A
    Endocrine; 2014 Sep; 47(1):177-82. PubMed ID: 24385266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DAXX Mutation Status of Embolization-Treated Neuroendocrine Tumors Predicts Shorter Time to Hepatic Progression.
    Ziv E; Rice SL; Filtes J; Yarmohammadi H; Boas FE; Erinjeri JP; Petre EN; Brody LA; Brown KT; Covey AM; Getrajdman GI; Maybody M; Raj N; Sofocleous CT; Solomon SB; Reidy-Lagunes D
    J Vasc Interv Radiol; 2018 Nov; 29(11):1519-1526. PubMed ID: 30342802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors.
    Osborne DA; Zervos EE; Strosberg J; Boe BA; Malafa M; Rosemurgy AS; Yeatman TJ; Carey L; Duhaine L; Kvols LK
    Ann Surg Oncol; 2006 Apr; 13(4):572-81. PubMed ID: 16511671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference.
    Kennedy A; Bester L; Salem R; Sharma RA; Parks RW; Ruszniewski P;
    HPB (Oxford); 2015 Jan; 17(1):29-37. PubMed ID: 25186181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors.
    Strosberg JR; Choi J; Cantor AB; Kvols LK
    Cancer Control; 2006 Jan; 13(1):72-8. PubMed ID: 16508629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival.
    Chen JX; Rose S; White SB; El-Haddad G; Fidelman N; Yarmohammadi H; Hwang W; Sze DY; Kothary N; Stashek K; Wileyto EP; Salem R; Metz DC; Soulen MC
    Cardiovasc Intervent Radiol; 2017 Jan; 40(1):69-80. PubMed ID: 27738818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors.
    Jia Z; Paz-Fumagalli R; Frey G; Sella DM; McKinney JM; Wang W
    J Gastroenterol Hepatol; 2017 Sep; 32(9):1617-1623. PubMed ID: 28132407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver transarterial embolizations in metastatic neuroendocrine tumors.
    de Mestier L; Zappa M; Hentic O; Vilgrain V; Ruszniewski P
    Rev Endocr Metab Disord; 2017 Dec; 18(4):459-471. PubMed ID: 28975561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice.
    Grozinsky-Glasberg S; Kaltsas G; Kaltsatou M; Lev-Cohain N; Klimov A; Vergadis V; Uri I; Bloom AI; Gross DJ
    Endocrine; 2018 Jun; 60(3):499-509. PubMed ID: 29383678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Arterial embolization of hepatic metastases from neuroendocrine tumors].
    Libicher M; Bovenschulte H
    Radiologe; 2009 Mar; 49(3):233-41. PubMed ID: 19183927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting periprocedural morbidity and mortality and long-term patient survival after arterial embolization of hepatic neuroendocrine metastases.
    Sofocleous CT; Petre EN; Gonen M; Reidy-Lagunes D; Ip IK; Alago W; Covey AM; Erinjeri JP; Brody LA; Maybody M; Thornton RH; Solomon SB; Getrajdman GI; Brown KT
    J Vasc Interv Radiol; 2014 Jan; 25(1):22-30; quiz 31. PubMed ID: 24365504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial.
    Chen JX; Wileyto EP; Soulen MC
    Trials; 2018 Jul; 19(1):390. PubMed ID: 30016989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.
    Gupta S; Johnson MM; Murthy R; Ahrar K; Wallace MJ; Madoff DC; McRae SE; Hicks ME; Rao S; Vauthey JN; Ajani JA; Yao JC
    Cancer; 2005 Oct; 104(8):1590-602. PubMed ID: 16134179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic arterial embolization in patients with neuroendocrine tumors.
    Del Prete M; Fiore F; Modica R; Marotta V; Marciello F; Ramundo V; Di Sarno A; Carratù A; di Roseto Cde L; Tafuto S; Tatangelo F; Baldelli R; Colao A; Faggiano A;
    J Exp Clin Cancer Res; 2014 May; 33(1):43. PubMed ID: 24887262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis.
    Egger ME; Armstrong E; Martin RC; Scoggins CR; Philips P; Shah M; Konda B; Dillhoff M; Pawlik TM; Cloyd JM
    J Am Coll Surg; 2020 Apr; 230(4):363-370. PubMed ID: 32032719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms.
    Brown KT; Koh BY; Brody LA; Getrajdman GI; Susman J; Fong Y; Blumgart LH
    J Vasc Interv Radiol; 1999 Apr; 10(4):397-403. PubMed ID: 10229465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged progression-free survival achieved by octreotide LAR plus transarterial embolization in low-to-intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden.
    Liu Y; Liu H; Chen W; Yu H; Yao W; Fan W; Li J; Chen M; Chen J; Wang Y
    Cancer Med; 2022 Jul; 11(13):2588-2600. PubMed ID: 35289113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and prognostic factors of transarterial embolization as initial treatment for spontaneously ruptured hepatocellular carcinoma: a single-center retrospective analysis in 57 patients.
    Zhou C; Zu QQ; Wang B; Zhou CG; Shi HB; Liu S
    Jpn J Radiol; 2019 Mar; 37(3):255-263. PubMed ID: 30511145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma.
    Maluccio MA; Covey AM; Porat LB; Schubert J; Brody LA; Sofocleous CT; Getrajdman GI; Jarnagin W; Dematteo R; Blumgart LH; Fong Y; Brown KT
    J Vasc Interv Radiol; 2008 Jun; 19(6):862-9. PubMed ID: 18503900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.